mortality/aging
• following adenoviral cre treatment, median survival time is 410 days
|
neoplasm
• following adenoviral cre treatment, 34% of mice develop thoracic tumors (including malignant mesotheliomas, 14 of 41) with a longer latency than in mice homozygous for all alleles
• following adenoviral cre treatment, 24% of mice develop aspecific tumors not induced by adeno-cre treatment
|
• in 17% of mice following adenoviral cre treatment
|
• following adenoviral cre treatment, 54% of mice develop monocytic myeloid leukemias
|
muscle
• in 17% of mice following adenoviral cre treatment
|
reproductive system
• in 17% of mice following adenoviral cre treatment
|